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Introduction: Esophageal cancer represents a major health care 
problem worldwide and its prevalence is rapidly increasing. A key 
challenge in the treatment of both locally advanced and metastatic 
disease is to improve our understanding of the underlying molecular 
biology. Herein we discuss the most active chemotherapies and tar-
geted agents for esophageal cancer, and explore potential differences 
in the disease between Eastern and Western countries.
Methods: We reviewed the literature for trials involving chemother-
apy and targeted agents in locally advanced and metastatic disease 
in the last 20 years. The search was supplemented by a review of 
the abstracts presented at the annual American Society of Clinical 
Oncology meetings from 1992 to 2012.
Results: Neoadjuvant chemo-radiation followed by surgery remains 
standard of care for operable disease. Definitive chemo-radiation can be 
considered for locally advanced squamous cell tumors. Platinum-based 
combination chemotherapy is preferable in the first-line metastatic set-
ting. Recently, HER2, EGFR, and VEGF–targeted agents have been 
extensively investigated as single agents or in combination with chemo-
therapy. Several new targets are being explored.
Conclusions: There have been incremental improvements in our 
understanding of the molecular biology of esophageal cancer, and 
ethnic differences between Asian and Western populations are becom-
ing apparent. Next-generation sequencing has failed to demonstrate 
significant oncogenic drivers; however, the addition of trastuzumab to 
chemotherapy for HER2-amplified tumors has been validated in the 
metastatic setting and is undergoing investigation in operable disease. 
Epigenetic therapeutics may provide additional benefit in future years 
for this difficult-to-treat disease.
Key Words: Esophageal cancer review, Targeted therapy, Esophageal 
Asia, Molecular biology, Esophageal squamous cell carcinoma, 
Esophageal adenocarcinoma.
(J Thorac Oncol. 2013;8: 673–684)
Esophageal cancer causes more than 400,000 deaths world-wide each year,1 and in the United States alone more than 
15000 deaths occurred because of this disease in 2012.2 The 
highest incidence of esophageal cancer is in Asia and eastern 
and southern Africa. In some areas of China, reported inci-
dence rates are 10- to 100-fold more than the incidence in the 
United States.3 The principle histologic types of esophageal 
cancer are esophageal squamous cell carcinoma (ESCC) and 
esophageal adenocarcinoma (EAC). The relative frequency of 
histologic subtypes differs greatly by geographical location. 
Over the last 30 years in Western Europe, North America, and 
Australia, there has been a dramatic shift in the histological 
subtypes from squamous cell to adenocarcinoma.4,5 This has 
been attributed to a decline in smoking and an increase in ade-
nocarcinoma risk factors including obesity, gastro-esophageal 
reflux disease, and Barrett’s esophagus. Adenocarcinoma has 
increased by an alarming 450% among white men in the last 
three decades.5 In Asia, where environmental toxins other than 
tobacco and alcohol may play a role in the origin of esopha-
geal cancer, ESCC continues to be most common and consti-
tutes a major health problem, particularly in China.6
Approximately 50% of esophageal cancers are localized 
or locoregionally advanced at diagnosis, and thus, amenable 
to potentially curative locoregional therapy.5 Five-year sur-
vival rates for all patients with esophageal cancer have shown 
modest improvements over the past 35 years from 5% to 
approximately 20% for patients diagnosed in 1975 and 2004, 
respectively.5 Survival for locoregionally advanced disease 
treated with surgery alone has been consistently poor, rang-
ing from 6% to 26% in published series.7–9 The high incidence 
of recurrence, both local and distant, after ostensibly curative 
surgery has provided the impetus for many studies of multimo-
dality therapy incorporating radiation and/or chemotherapy, 
primarily in the neoadjuvant setting, aimed at reducing the 
overall risk of relapse and death. Unfortunately, the appropri-
ate management of locally advanced disease has been conten-
tious for a number of years, and no clear standard of care has 
been defined that could be accepted worldwide. For patients 
with adenocarcinoma, there are clinical trial data supporting 
the various approaches of induction concurrent chemo-radi-
ation (CRT), induction chemotherapy, perioperative chemo-
therapy, or resection after adjuvant CRT. Recent data suggest 
that preoperative CRT is superior to surgery alone.10
This review will focus on recent therapeutic developments 
for esophageal cancer, including the recently published phase 
III clinical trials for both resectable and metastatic disease 
and ongoing trials evaluating targeted therapy and biomarker-
driven investigations. Given the particularly high burden of 
esophageal cancer in Asia,  randomized studies of esophageal 
cancer therapy conducted in Asian populations will be 
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reviewed for insights on geographic and ethnic differences in 
tumor biology and response to therapy. 
MATERIALS AND METHODS
Information for this review was derived after searching 
the PubMed and MEDLINE databases for significant chemo-
therapy, chemo-radiation, and targeted-agent clinical trials 
that have been conducted in esophageal cancer over the last 20 
years. Only articles with an abstract in English were included, 
thus a slight amount of publication bias cannot be excluded. 
The search was supplemented by a review of abstracts pre-
sented at the American Society of Clinical Oncology annual 
meetings from 1992 to 2012 whereas ongoing unpublished tri-
als were evaluated on the clinicaltrials.gov website.
RESULTS
Treatment of Stage II and Stage III Disease
Perioperative chemotherapy
Multiple studies have evaluated the role of neoadjuvant 
chemotherapy before definitive surgery for esophageal can-
cer (Table 1).11–13 Cisplatin-based combinations result in 50% 
or more regression of tumor in half of the patients, however, 
a pathological complete response (pCR) occurs in only 2% 
to 6% of all patients.9,11–13 A large U.S. Intergroup study, and 
several other smaller studies conducted in Europe, showed no 
survival benefit to preoperative chemotherapy followed by sur-
gery, when compared with surgery alone.9,11,14 Conflicting data 
arose from the MRC–OEO2 study conducted in the United 
Kingdom, which reported a 5-year survival advantage of 6% 
for neoadjuvant chemotherapy when compared with surgery 
alone.12 Similarly, a Japanese study, comparing preoperative 
chemotherapy with postoperative chemotherapy in patients 
with squamous cancer, suggested a survival advantage for 
preoperative therapy of 12% at 5 years.15 Notably, this study 
did not have a surgery-only control arm.
Several phase III studies of perioperative chemotherapy, 
primarily looking at gastric cancer, have enrolled subpopula-
tions of patients with lower esophageal or gastro-esophageal 
junction (GEJ) adenocarcinoma. The MAGIC study con-
ducted in the United Kingdom included 26% of patients with 
lower esophageal or GEJ adenocarcinoma.16 This study dem-
onstrated a 13% improvement in 5-year survival for patients 
who received multiagent epirubicin, cisplatin, and fluorouracil 
(ECF) chemotherapy for three cycles preoperatively followed 
by another three cycles, postoperatively. Subgroup analyses 
suggested that the trend for improved survival was preserved 
in the group of patients with lower esophageal or GEJ tumors. 
A French study by Ychou et al.13 randomized 224 adenocar-
cinoma patients (72% esophageal or GEJ tumors) to two or 
three cycles of preoperative cisplatin/5-flourouracil (FU) fol-
lowed by three or four cycles of postoperative therapy; of note, 
only 50% of patients who received at least one cycle of preop-
erative chemotherapy actually received postoperative therapy. 
Despite closing early because of poor recruitment, this study 
showed at 5 years a significant survival advantage of 14% in 
favor of the chemotherapy group over surgery alone. In 2011, a 
meta-analysis of preoperative chemotherapy suggested a haz-
ard ratio (HR) for all-cause mortality of 0.87 (95% confidence 
interval [CI], 0.79–0.96) in favor of chemotherapy, compared 
with surgery alone, which translated to a 2-year absolute sur-
vival advantage of 5%.17 Analysis by histology suggested a 
significant benefit to neoadjuvant chemotherapy for adeno-
carcinoma, HR 0.83 (0.71–0.95; p = 0.01), however, the ben-
efit for squamous tumors did not reach significance, HR 0.92 
(0.81–1.04; p = 0.18). At present, we consider perioperative 
TABLE 1.  Selected Studies of Perioperative Chemotherapy for Esophageal Cancer
Study T Stage Histology Chemotherapy Outcome
Kelsen et al.9 (United States)
N = 440
T1–3 Adeno–53%
Squamous–46%
Preoperative
Cis/5-FU × 3 cycles
3-yr OS (ns)
Sx–26%
C–Sx–23%
Ancona et al.11 (Europe)
N = 96
T2–3 Squamous–100% Preoperative
Cis/5-FU × 3
3-yr OS (ns)
Sx–41%
C–Sx–44%
MRC–OEO2 Study (Europe) 2009
N = 802
T1–3 Adeno–66%
Squamous–31%
Preoperative
Cis/5-FU × 2
5-yr OS (s)
Sx–17.1%
C–Sx–23%
Cunningham et al.16 (United Kingdom)
N = 503
T2–3 Adeno–100%
(Lower esophageal 14.5%,  
GEJ 11.5%, gastric 74%)
Preoperative ECF × 3 and 
postoperative ECF × 3
5-yr OS (s)
Sx–23%
C –Sx –C–36%
Ychou et al.13 (France) 
N = 224
T1–3 Adeno–100% (Lower esophageal  
11.2%, GEJ 61.2%, gastric 27.6%)
Preoperative cis/5-FU × 2–3 and 
postoperative cis/5-FU × 3–4
5-yr OS (s)
Sx–24%
C–Sx–C–38%
Ando et al.15 (Japan) 
N = 330
T2–3 Squamous–100% Preoperative cis/5-FU × 2 or  
postoperative cis/5-FU × 2
5-yr OS (s)
Sx–C–43%
C–Sx–55%
Schuhmacher et al.14 (EORTC–Germany)
N = 144
T3–4 Adeno–100% (GEJ/proximal  
stomach–52.8% gastric–47.2%)
Preoperative cis/5-FU × 2 2 yr OS (ns)
Sx–69.9%
C–Sx–72.7%
OS, overall survival; C, chemotherapy; Sx, surgery; (s), statistically significant difference; (ns) statistically not significant; ECF, epirubicin cisplatin 5-flourouracil; 
GEJ, gastroesophageal junction; FU, flourouracil.
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chemotherapy in tumors of the GEJ that are classified as 
Siewert stage 3 and where a gastric origin is favored.
Preoperative CRT
Many trials have been conducted to address the poten-
tial benefit of preoperative concurrent CRT, using either sur-
gery alone or preoperative radiation followed by surgery as a 
control arm (Table 2). In general, these trials report a pCR in 
25% to 30% of patients with associated long-term survival 
for this subset.7,18,19 Approximately two thirds of patients are 
down-staged after preoperative CRT. Median survival rates 
with multimodality therapy (CRT followed by surgery) in 
recent studies exceed 2 years, and 3-year and 5-year survival 
rates are in the 30% to 40% range in Western studies. These 
outcomes compare favorably with historic series of surgery 
alone, which demonstrated 5-year survival rates of 15% to 
20%. The first randomized study to show a survival advantage 
for multimodality therapy was published in 1996, however, 
it was criticized for nonuniform staging of patients and the 
poor survival rate of the surgery-only control arm patients.7 
However, this study encouraged the adoption of multimodal-
ity therapy as a standard of care in the United States.
Subsequently, several other studies published during the 
2000s failed to support a survival advantage for the multimo-
dality approach.18–20 Many of these studies had flaws, including 
utilizing suboptimal chemotherapy and radiation schedules,19 
being statistically underpowered,20 or adopting lower radiation 
dosing.21 Importantly, these studies did suggest that achieving 
pCR was prognostically important after preoperative therapy 
with a significant improvement in overall survival (OS) for 
those achieving pCR.19
The U.S. CALGB 9781 study, which closed early 
because of poor recruitment, did report a significant survival 
advantage for multimodality therapy. However, because 
of the small number of patients enrolled, (56 in total, 75% 
adenocarcinoma), the wider relevance of the results were 
questionable.21 In France, Mariette et al.22 reported a 13-month 
increase in OS for multimodality over surgery alone, but this 
difference did not meet statistical significance. Most recently, 
the Dutch CROSS study, published in 2012, confirmed the 
benefits of multimodality treatment in esophageal cancer.10 
This large, well-conducted study examined weekly, low-
dose, radio-sensitizing carboplatin (area under the curve 2)/
paclitaxel (50 mg/m2) chemotherapy for 5 weeks concurrent 
with a standard radiation schedule followed by surgery 
compared with surgery alone. Patients predominantly had 
adenocarcinoma (74.7%), with 24% having tumors of the 
GEJ. Multimodality treatment was well tolerated with more 
than 90% of patients receiving all the scheduled chemotherapy 
and radiation. R0 resections were significantly more frequent 
after preoperative therapy (92% versus 69% for surgery alone, 
p < 0.001), lymph-node positivity at resection was markedly 
reduced by preoperative therapy (31% versus 75%, p < 0.001 
for surgery alone), and there was no increase in postoperative 
TABLE 2.  Selected Studies of Preoperative Chemo-Radiation
Study Histology Concurrent Arm Control Arm Outcome
Walsh et al.7 (Ireland) 
N = 113
Adeno–100% Cisplatin/5-FU × 2 
4000 cGy
Surgery alone Median OS (s)
Sx–11 mo
CRT–Sx–16 mo
Bosset et al.18 (France) 
N = 282
Squamous–100% Cisplatin × 2 
5000 cGy
Surgery alone Median OS (ns)
CRT–Sx–18.6 mo
Sx–18.6 mo
Urba et al.19 (United States) 
N = 100
Adeno–75%
Squamous–25%
Cisplatin/5-FU/vinblastine × 2 
4500 cGy
Surgery alone Median OS (ns)
Sx–17.6 mo
CRT–Sx–16.9 mo
Burmeister et al.20 (Australia), 
N = 256
Adeno–61.7%
Squamous–37%
Cisplatin/5-FU × 2 
3500 cGy
Surgery alone Median OS (ns)
Sx–19.3 mo
CRT–Sx–22.2 mo
Carstens et al.26 (Sweden) 
N = 91
Adeno–50%
Squamous–50%
Cisplatin/5-FU × 3 
(1 induction  pre-CRT) 
6400 cGy
Surgery alone Median OS (ns)
Sx–15.8 mo
C–CRT–Sx–12.8 mo
Tepper et al.21 CALGB (United States)
N = 56
Adeno–75%
Squamous–25%
Cisplatin/5-FU × 2 
5040 cGy
Surgery alone Median OS (s)
Sx–21.5 mo
CRT–Sx–53.8 mo
Stahl et al.25 (Germany)
N = 126
Adeno–100% Cisplatin/5-FU × 12 wks followed 
by CRT
Cisplatin/5-FU ×  
15 weeks
3-yr survival (ns)
C–CRT–Sx–47.4%
C–Sx–27.7%
Mariette et al.22 (France) 
N = 195
Squamous–69%  
Adeno–31%
Cisplatin/5-FU × 2 
4500 cGy
Surgery alone Median OS (ns)
Sx–31.8 mo
CRT–Sx–44.5 mo
van Hagen et al.10 CROSS (Dutch) 
N = 368
Adeno–74.7% 
Squamous–22.8% 
GEJ tumors–24%
Carboplatin/paclitaxel weekly × 5 
4140 cGy in 23 fractions
Surgery alone Median OS (s)
Sx–24 mo
CRT–Sx–49.4 mo
OS, overall survival; CRT, chemo-radiotherapy; Sx, surgery; (s), statistically significant difference; (ns) difference not statistically significant; cGy, centiGray; fr, fractions; bid, 
twice daily; C, induction chemotherapy; GEJ, Gastroesophageal junction; C, chemotherapy; FU, flourouracil.
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morbidity or mortality. Median OS was more than doubled 
for patients who received multimodality therapy (49.4 months 
versus 24 months for surgery alone, p = 0.011), and the benefit 
of multimodality therapy seemed to be preserved across 
tumor histological subtypes and all other stratified variables. 
Interestingly, in this study although there was a higher rate of 
pCR with preoperative therapy for squamous (49%) compared 
with adenocarcinomas (23%), this did not translate into better 
outcomes for patients with squamous histology.
Sequential chemo-radiation, postoperative chemotherapy, 
and other strategies
In contrast to concurrent preoperative chemo-radiation, 
several studies have demonstrated no benefit to sequentially 
administered preoperative chemotherapy followed by radia-
tion when compared with surgery alone, and as a consequence, 
we do not recommend this strategy.23,24
Several studies have addressed the role of induction 
chemotherapy followed by CRT before surgery. The German 
POET study compared 15 weeks of preoperative chemo-
therapy alone (cisplatin/5FU) with sequential treatment of 12 
weeks of induction chemotherapy, followed by preoperative 
chemo-radiation (cisplatin/etoposide) in 126 patients with 
gastric cardia or GEJ tumors.25 This study was closed early 
because of poor accrual, however, there was a strong trend 
toward improved 3-year survival for patients who received pre-
operative CRT (3-year survival: chemo 27.7%, CRT 47.4%, p 
= 0.07). In addition, patients who received CRT had signifi-
cantly higher pCR rates (15.6% versus 2.0% for chemo alone, 
p = 0.03) and negative lymph node status at surgery (64.4% 
versus 37.7% for chemo alone, p = 0.01). In Sweden, a ran-
domized study of 91 patients, comparing one cycle of induc-
tion chemotherapy before CRT versus surgery alone, failed 
to demonstrate a benefit for induction chemotherapy followed 
by CRT.26 More recently, a phase II study evaluated induction 
chemotherapy with cisplatin/irinotecan followed by the same 
chemotherapy concurrent with radiation in 55 patients with 
operable esophageal cancer.27 The pCR rate in this study was 
relatively low at 16% with modest progression-free survival 
(PFS) and OS rates.
Although data from the POET study are promising, 
because of the lack of a preoperative CRT-alone arm in that 
study, questions remain regarding the true role of induction 
chemotherapy before CRT in multimodality treatment of 
esophageal cancer. Given the results of the larger CROSS 
study, which did not incorporate induction chemotherapy and 
showed excellence tolerability of CRT, at present we favor 
CRT without induction chemotherapy for the majority of our 
patients.
For good performance status patients with resected 
node-positive GEJ tumors, who have not received preopera-
tive therapy, adjuvant CRT should be considered. The U.S. 
Intergroup study randomly assigned 556 patients with resected 
gastric (80%) or GEJ (20%) adenocarcinoma to observation 
or adjuvant chemo-radiation with 5-FU/leucovorin (4 cycles, 
2 during radiation).28 Median OS was significantly increased 
for patients who received adjuvant chemo-radiation (surgery 
alone 27 months versus adjuvant CRT 36 months, p = 0.005). 
Recently updated analyses of this study confirm a persistent 
survival benefit at 10 years from adjuvant CRT.29 The opti-
mal treatment for patients with resected esophageal squamous 
carcinoma is unclear, with some single-arm studies and ret-
rospective data indicating a benefit from adjuvant CRT and 
some others suggesting that the contribution of radiation may 
be marginal.30,31 The benefit of adjuvant chemotherapy for 
resected esophageal squamous carcinoma was assessed in a 
Japanese study, which compared surgery alone with surgery 
followed by adjuvant cisplatin/5-FU in 242 patients.32 This 
study met its primary endpoint of improving disease-free sur-
vival (45% of 5-year disease-free survival for surgery alone 
versus 55% for adjuvant chemotherapy; p = 0.037), however, 
OS was not significantly improved (52% versus 61%).
Nonsurgical Management of Esophageal  
Cancer
Definitive CRT
The landmark trial of definitive CRT was the RTOG 
85-01 study, in which patients with locally advanced esopha-
geal cancer were randomized to chemo-radiotherapy or radio-
therapy alone.33,34 Chemotherapy consisted of 5-FU (1000 mg/
m2/24 hours × 4 days) and cisplatin (75 mg/m2, day 1), which 
was given on the first day of weeks 1, 5, 8, and 11. Radiation 
therapy (5000 cGy/25 fractions) was begun concurrently with 
day 1 of chemotherapy. Four cycles of chemotherapy were 
given—two during radiotherapy and two after radiotherapy. 
The control arm consisted of radiation alone of 6400 cGy in 
32 fractions. Only 50% of patients were able to complete all 
four cycles of chemotherapy. Patients receiving CRT had a 
significant improvement in median survival (14 months versus 
9 months) and 5-year survival (26% versus 0%; p < 0.0001). 
The incidence of local failure (defined as persistent disease or 
recurrence) at 1 year was significantly decreased in the com-
bined modality arm (45% versus 68%; p = 0.0123). Although 
randomization was discontinued early because of the positive 
results, an additional 69 patients treated with the same CRT 
regimen had similar results (3-year survival 30%). Despite a 
survival benefit, there was an unacceptably high local failure 
rate (45%) in RTOG 85-01, suggesting that definitive CRT 
should be reserved for patients who are medically precluded 
from surgery.
Chemotherapy for metastatic esophageal cancer
Median survival for good performance status patients 
treated with combination chemotherapy for advanced unre-
sectable or metastatic esophageal cancer ranges from 8 to 11 
months in randomized studies (Table 3).35–37 The majority of 
studies have included both histologic subtypes along with a 
mixed group of esophageal, GEJ, and gastric tumor patients. 
With the relatively increasing incidence of EAC, randomized 
studies have frequently included esophageal, GEJ, and gas-
tric adenocarcinoma patients, and retrospective analysis of 
these studies does not seem to show a difference in response 
to chemotherapy or survival, on the basis of tumor location.38 
Response rates from platinum/fluoropyrimidine combination 
studies have ranged from 24% to 58% with median survival 
of 8 to 16 months.36,39 ECF was compared with a previous 
reference regimen, fluorouracil, doxorubicin, and methotrex-
ate (FAMTX) in 274 patients with advanced GEJ cancer.40–42 
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This study included approximately 10% of patients who had 
surgical resection of their tumors after initial chemotherapy, 
indicating a more favorable cohort than subsequent phase 
III studies. Median survival was 8.7 months with ECF and 
6.1 months with FAMTX, p value was 0.0005, response 
rates were 46% for ECF and 21% for FAMTX, respectively. 
Subsequently, ECF was compared with combination cisplatin, 
fluorouracil, and mitomycin (MCF). This study demonstrated 
similar response rates and survival for each arm; however, 
reduced quality of life was noted with MCF, leading to ECF 
remaining standard of care.43
The phase III TAX-325 study compared the three-drug 
combination of docetaxel, cisplatin, and fluorouracil (DCF) 
with the two-drug combination of cisplatin and fluorouracil 
in 317 advanced gastric and GEJ adenocarcinoma patients of 
whom approximately 20% had GEJ tumors with a primary 
endpoint of time to tumor progression (TTP).44 Patients treated 
with DCF had a significantly prolonged TTP (5.6 months ver-
sus 3.7 months, p < 0.001) and also prolonged OS (9.2 months 
versus 8.6 months; p = 0.02). Quality-of-life assessments indi-
cated that deterioration in global health status was significantly 
delayed in the DCF group, however, grade 3 to 4 febrile neu-
tropenia was more than twice as common (29% versus 12%) 
in the DCF group, and GCSF support is now recommended 
with this regimen. Although DCF is a reference regimen for 
advanced GEJ and gastric cancer, the marginal prolongation 
of OS and significant toxicity with this regimen spurred the 
search for more effective treatments. In 2008, the REAL-2 
trial compared four different three-drug combinations, ECF, 
epirubicin, cisplatin, and capecitabine (ECX), epirubicin, 
oxaliplatin, and capecitabine (EOX), and epirubicin, oxalipla-
tin, and infusional fluorouracil (EOF) in 1002 patients with 
tumors of the stomach, GEJ, or esophagus.35 Approximately 
60% of patients had esophageal or GEJ primary tumors, and 
10% of the tumors had squamous histology. Efficacy was sim-
ilar for all arms, both for capecitabine-containing regimens 
compared with fluorouracil, and oxaliplatin-based regimens 
compared with cisplatin. Median survival was significantly 
prolonged for the EOX group compared with ECF (median 
11.2 versus 9.9 months), leading to EOX being proposed as 
a new standard first-line treatment for advanced esophageal 
and gastric cancer. A recent meta-analysis has also suggested 
advantages in PFS and OS for oxaliplatin-containing regi-
mens over cisplatin-containing alternatives.45
Esophageal cancer in Asia and ethnic differences in mo-
lecular biology
Esophageal cancer is a major health problem in Asia 
with incidence rates in Eastern Asia between two- and four-
fold than those of North America, with more than two thirds 
of cancers occurring in men.1 In contrast to white populations, 
among Asians squamous cell carcinoma is the predominant 
subtype, accounting for 90% of the cases in the esophageal 
cancer belt, which is the region stretching from northern Iran 
to north-central China.3
Several reasons for this high incidence have been pro-
posed, including frequent consumption of very hot beverages, 
poor nutrition, and low intake of fruit and vegetables.6,46,47 
Single-gene polymorphisms in alcohol-metabolizing enzymes 
in certain Asian populations have also been implicated, which 
may predispose Asians to the development of esophageal 
cancer related to alcohol intake.48,49 Deletion or loss of het-
erozygosity on chromosome 3p, leading to loss of tumor-sup-
pressor gene function has been implicated in the development 
of ESCC among patients in China.50 In addition, mutations of 
p53 affecting codon 72 have been found in Chinese patients 
with ESCC at a much higher frequency than in white patients, 
suggesting a possible etiologic role in Asian patients.50,51
Reflecting the baseline incidence, randomized studies of 
perioperative therapy for esophageal cancer in Asia have focused 
on squamous tumors (Table 4).52–58 Earlier studies examining 
the role of preoperative or postoperative chemotherapy failed 
to demonstrate a survival advantage for systemic therapy.52–54 
Of note, Asian studies of the oral fluoropyrimidine S-1 have 
shown particular promise in gastric cancer, and studies are 
ongoing of this drug as a component of multimodality therapy 
for esophageal cancer and for the treatment of advanced 
disease.59,60 S-1 has shown improved tolerance and comparable 
efficacy to 5-FU-based combination chemotherapy in a large 
international phase III study in gastric cancer, which included 
17% of patients with metastatic GEJ tumors.59
Although studies of perioperative therapy in Asia 
reported in the 1990s demonstrated similar median survival to 
North American and European randomized populations, more 
recent studies, in particular those from Japan, have shown a 
consistent median survival of close to 5 years, which is yet to 
be matched in a Western phase III trial population.15,32,56 As 
an example median survival in two recently published phase 
III studies from Japan and Europe have differed dramatically 
despite relatively well-matched enrolled patient populations 
for characteristics other than histologic subtype.10,15 The 
Asian study, JCOG 9907, randomized 330 patients with 
stage II or III ESCC to either preoperative or postoperative 
chemotherapy with cisplatin/fluorouracil.15 Median survival 
for the postoperative chemotherapy group was 101.3 months, 
and median survival for the preoperative group, though not yet 
evaluable, however, exceeds 5 years.56 Although the European 
CROSS study, which included mainly adenocarcinoma tumors, 
has demonstrated the longest median survival seen to date in a 
large Western study at 49.4 months for the preoperative CRT 
group, it still lags significantly behind studies from Asia.10 The 
reasons for these differences, though unclear may, however, 
be related to histology, extent of surgery, and perhaps more 
significantly, underlying genetic differences in tumor biology.
Targeted agents for esophageal cancer
Although multimodality therapy has become the stan-
dard procedure for treatment of locoregionally advanced 
esophageal cancer, unfortunately, more than 50% of patients 
will eventually develop recurrence and die from their disease. 
This has spurred the search for agents that target specific path-
ways in tumor cells vital to proliferation and metastatic spread. 
Although initially many of these studies involved patients 
with metastatic disease, these agents are now increasingly 
being investigated in the preoperative setting as a component 
of multimodality therapy. Selected current and completed 
studies involving molecularly targeted agents in the treatment 
of locoregionally advanced disease are summarized in Table 5.
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Epidermal growth factor receptor
To date, the majority of studies on perioperative tar-
geted therapy have focused on the epidermal growth factor 
receptor (EGFR) pathway. The incidence of EGFR expres-
sion by immunohistochemistry (IHC) or fluorescence in situ 
hybridization (FISH) in esophago-gastric tumors has been 
reported with varying expression rates of 30% to 90%, and 
the presence of EGFR suggests a worse prognosis.61,62 EGFR 
overexpression varies depending on histology, with expres-
sion rates being higher in ESCC than in EAC.63 Unlike in 
non–small-cell lung cancer, EGFR mutations are extremely 
rare in esophageal tumors, limiting the activity of the 
small-molecule tyrosine kinase inhibitors (TKIs), erlotinib 
and gefitinib, in this setting.64 K-ras mutations are rare in 
esophageal cancer, and recent studies have reported that only 
one of 203 analyzed ESCC tumors harbored a K-ras muta-
tion, whereas four of 117 EAC tumors were K-ras mutation 
positive.65,66
Cetuximab and panitumumab are monoclonal antibod-
ies targeted at the epidermal growth factor (EGF) receptor 
and are approved for the treatment of metastatic colorectal 
cancer.67,68 Several phase II studies combining these agents 
with CRT are either ongoing or have completed accrual in 
the perioperative setting (Table 5). Cetuximab has undergone 
more extensive evaluation in esophageal cancer than any 
other targeted agent. In the locally advanced setting, various 
chemotherapeutic regimens, including cisplatin/irinotecan, 
carboplatin/paclitaxel, cisplatin/docetaxel, and FOLFOX have 
been combined with cetuximab and radiation before surgery. 
pCR, which is regarded as a surrogate marker of long-term 
survival, has ranged from 13% to 40% in these trials. With the 
use of cetuximab in the neoadjuvant setting it is found that the 
pCR rates seem to be comparable with preoperative chemo-
radiation alone, though perhaps with more toxicity. The 
Eastern Cooperative Oncology Group E2205 trial, incorporat-
ing cetuximab with chemo-radiation, closed early because of 
an excess of pulmonary toxicity in the treatment group. The 
adenocarcinoma arm of the phase III, RTOG 0436 study, com-
paring weekly cisplatin/paclitaxel/radiation ± cetuximab as 
definitive therapy in locally advanced esophageal cancer, also 
closed as there was no evidence of increased pCR rate in the 
adenocarcinoma group; however, patients with squamous cell 
carcinoma continue to accrue. The phase II study, ACOSOG 
Z4051, combining panitumumab with cisplatin, docetaxel, 
and radiation, recently reported a promising pCR and near 
pCR rate of more than 55%, and has now completed accrual.69 
It is likely that this combination will move on to phase III 
investigation in the near future.
In the metastatic setting, cetuximab has been combined 
with a multitude of regimens in the first-line setting, with many 
trials not mandating upfront patient selection based on EGFR 
positivity. A trial investigating FOLFIRI plus cetuximab with 
TABLE 3.  Randomized Studies of Systemic Therapy for Advanced Esophageal and GEJ Cancer
Study Investigational Arm(s) Control Primary site (%) Histology Outcome
Bleiberg et al.36 
N = 92
CF Cisplatin 100% esophageal squamous RR (s): CF–35%,
cisplatin–19%
OS–(ns)
Vanhoefer et al. (2000) 
N = 399
ELF or CF FAMTX Gastric adenocarcinoma RR (ns): CF–20%
ELF–9%
FAMTX 12%
OS–(ns)
Webb et al.41 
N = 274
ECF FAMTX Esophageal–20%
GEJ–24%
100% adeno
OS–(s)
ECF–8.9 mo
FAMTX–5.7 mo
Ross et al.43 
N = 580
MCF ECF Esophageal–32%
GEJ–22%
Adeno–82%
Squamous–7%
OS–(ns)
ECF–9.4 mo
MCF–8.7 mo
Van Cutsem et al.44 
N = 445
DCF CF GEJ–22%
Gastric–78%
Adeno–100%
OS–(s)
DCF–9.2 mo
CF–8.6 mo
Cunningham et al.35 
N = 1002
EOX, EOF, ECX ECF Esophageal–33%
GEJ–25%
Adeno–90%
Squamous–10%
OS
EOX–11.2 mo (s)
EOF–9.3 mo
ECX–9.9 mo
ECF–9.9 mo
Koizumi et al. (2010) 
N = 1053
Cisplatin + S-1 Cisplatin + infusional  
5-FU
GEJ–17%
Gastric–83%
OS (ns)
Cisplatin/S-1–8.6 mo
Cisplatin/5-FU 7.9 mo
Bang et al.79 
N = 594
Trastuzumab with CF or  
CX chemotherapy
CF or CX GEJ–18%
Stomach 82%
Adenocarcinoma 100%
OS (s)
Trast /chemo–13.8 mo
Chemo–11.1 mo
CF, cisplatin/5-flourouracil (5-FU); RR, response rate; OS, overall survival; ELF, etoposide/leucovorin/5-FU; FAMTX, high-dose methotrexate, 5-FU, doxorubicin; ECF, epirubicin/
cisplatin/5-FU; GEJ, gastro-esophageal junction; MCF, mitomycin/5-FU/cisplatin; DCF, docetaxel/cisplatin/5-FU; EOX, epirubicin/oxaliplatin/capecitabine; EOF, epirubicin/
oxaliplatin/5-FU; ECX, epirubicin/cisplatin/capecitabine; CX, cisplatin/capecitabine.
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patients selected by IHC EGFR positivity reported response 
rates of 44% and a median OS of 9 to 16 months, however, the 
degree of EGFR positivity did not correlate with response.70 
The results of the randomized phase II CALGB study 80403 
combining cetuximab with one of the three randomly assigned 
regimens of ECF, cisplatin/irinotecan, or FOLFOX were 
recently reported.71 Cetuximab plus ECF or FOLFOX had 
response rates of more than 40%; biomarker correlatives of 
EGFR expression and Kras status are currently awaited. The 
phase III EXPAND study did not demonstrate any benefit to 
the addition of cetuximab to cisplatin/capecitabine in recently 
reported data.72
The REAL-3 trial in the United Kingdom is attempt-
ing to build on the REAL 2 study by randomizing patients 
with advanced GEJ tumors to EOX ± panitumumab. The 
doses planned originally resulted in significant toxicities, 
with an 80% rate of grade 3 diarrhea. The study was halted 
for a period of time but was subsequently resumed with lower 
doses of capecitabine and oxaliplatin and standard dosing of 
panitumumab at 6 mg/kg every 2 weeks.73 To date, it is not 
clear whether the addition of monoclonal antibodies to che-
motherapy is warranted because of the conflicting data from 
the many small trials that have been performed. In the second-
line setting and beyond, preliminary data involving EGFR-
directed therapy has been disappointing.
The TKIs, erlotinib and gefitinib, have limited activity in 
locally advanced disease in the first- or second-line metastatic 
setting. Gefitinib, in addition to perioperative 5FU/cisplatin/
radiation, was evaluated in 80 patients with locally advanced 
disease and demonstrated a trend toward an improved 3-year 
OS in the gefitinib arm (40% versus 28%; p = 0.06).74 
Maintenance gefitinib was poorly tolerated postoperatively. In 
the second-line metastatic setting, results for both TKIs have 
also been disappointing. Response rates have ranged from 3% 
to 11% with OS of 4.5 months to 5.1 months.64,75 The SWOG 
0127 phase II trial evaluated first-line erlotinib in advanced 
disease, patients were stratified into GEJ (44 patients) and gas-
tric (26 patients).76 There were no responses in patients with 
gastric cancer, and an ORR of 9% was seen in GEJ patients. 
No EGFR or EGFR gene amplifications were detected in 54 
samples, indicating that the tumor biology of upper gastro-
intestinal tumors is not conducive to EGFR-directed small-
molecule TKI therapy.
HER-2/neu therapy
The human epidermal growth factor receptor 2 (HER2) 
pathway is up-regulated in 12% to 14% of EAC tumors and 
less than 1% of squamous tumors.77,78 The phase III ToGA 
study compared a cisplatin/fluoropyrimidine combination 
plus or minus trastuzumab as first-line therapy for 
metastatic gastric or GEJ adenocarcinoma overexpressing 
HER2.79 In this pivotal trial, 22.1% of tumors were found 
to be Her-2/neu positive by IHC or FISH, and 594 patients 
were randomly assigned to study treatment (trastuzumab 
TABLE 4.  Randomized Studies of Perioperative Therapy for ESCC in Asia  
Study Perioperative Arm Control(s) Outcome
Maipang et al.52 (Thailand) 
N = 46
Preoperative cisplatin/bleomycin/vinblastine × 2 cycles.  
No radiation
Surgery alone Median OS (ns)
C–Sx–17 mo
Sx–17 mo
Law et al.53 (Hong Kong) 
N = 147
Preoperative cisplatin/5FU × 2 cycles. No radiation Surgery alone Median OS (ns)
C–Sx–16.8 mo
Sx–13 mo
Ando et al.54 (Japan) 
N = 205
Postoperative cisplatin/vindesine × 2 cycles.  
No radiation
Surgery alone 5-yr OS (ns)
Sx–C–48%
Sx–45%
Tachibana et al.31 (Japan) 
N = 103
Postoperative cisplatin/5FU × 2 cycles 5000 cGy in 25 Fr Postoperative cisplatin/5FU × 2.  
No radiation
Median OS (ns)
Sx–C–28 mo
Sx–CRT–31 mo
Ando et al.32 (Japan) 
N = 242
Postoperative cisplatin/5FU × 2. No radiation Surgery alone 5-yr OS (ns)
Sx–C–61%
Sx–52%
Lee et al.57 (Korea) 
N = 101
Preoperative cisplatin/5-FU × 2 cycles 4560 cGy in  
28 Fr If stable or response to CRT → received  
postop cis/5FU × 3
Surgery alone Median OS (ns)
CRT–Sx–28.2 mo
Sx–27.3 mo
Natsugoe et al.55 (Japan) 
N = 50
Preoperative cisplatin/5FU × 2 cycles 4000 cGy in 20 Fr Surgery alone 5-yr OS (ns)
CRT–Sx–57%
Sx–41%
Lu et al.58 (China)
N = 158
Preoperative cisplatin/paclitaxel × 2 cycles 4000 cGy in 20 Fr Surgery alone or postoperative CRT Median OS (s)
CRT–Sx–53 mo
Sx–CRT–48 mo
Sx–36 mo
Ando et al.15 (Japan) 
N = 330
Preoperative cisplatin/5-FU × 2. No radiation Postoperative cisplatin/5-FU × 2.  
No radiation
5-yr OS (s)
C–Sx–55%
Sx–C–43%
ESCC, esophageal squamous cell carcinoma; OS, overall survival; (ns), difference not statistically significant; (s), difference statistically significant; C, chemotherapy; Sx, surgery; 
cGy, centiGray; CRT, concurrent chemo-radiation; FU, fluourouracil.
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plus chemotherapy, n = 298; chemotherapy alone, n = 296), 
of whom 584 were included in the primary analysis (n = 
294; n = 290). The report of this study outlines in detail 
the mechanism used to assess HER2 positivity.79 Median 
OS was 13.8 months (95% CI, 12–16) in those assigned 
to trastuzumab plus chemotherapy, compared with 11.1 
months (10–13) in those assigned to chemotherapy alone 
(HR 0.74; 95% CI, 0.60–0.91; p = 0.0046). The ToGA trial 
is the first positive phase III trial of a targeted agent in upper 
GI tumors. Unfortunately, because of the limited incidence 
of HER-2 positive disease this strategy will be beneficial 
only for a minority of patients.
TABLE 5.  Selected Completed and Ongoing Studies of Targeted or Pathway-Specific Agents in Esophageal/GEJ Cancer
Phase NCT Identifier Agent(s), Schedule Population/Status/Results
EGFR/HER2
II NCT00551759 (E2205) Preoperative cetuximab/5-FU/oxaliplatin/radiationPostoperative– 
docetaxel/cetuximab
Closed–excess pulmonary toxicity
III NCT00655876 (RTOG 
0436)
Preoperative paclitaxel/cisplatin/radiation ± cetuximab Adeno arm–closed futility squamous arm–recruiting
II NCT00757172 (ACOSOG 
Z4051)
Preoperativecisplatin/docetaxel/radiation ± panitumumab Completed accrual pCR and near pCR 55.2%
III NCT00680901 (LOGIC) capecitabine/oxaliplatin ±lapatinib First-line metastatic HER2 positive EAC/GEJ/gastric 
cancer. Completed accrual
III NCT00486954 Paclitaxel ± lapatinib Second-line metastatic HER2 positive EAC/GEJ/
gastric cancer. Completed accrual
I/II NCT01128387 Preoperative cisplatin/5FU/radiation and panitumumab Locally advanced esophageal/GEJ cancer
I NCT01705340 Lapatinib + trastuzumab + MK2206 (Akt inhibitor) HER2-positive metastatic GEJ or gastric cancer
II NCT01743365 Cisplatin/5-FU/afatinib (irreversible EGFR TKI) Metastatic GEJ or gastric cancer
II NCT01461057 Cisplatin/capecitabine + trastuzumab ± pertuzumab HER2-positive metastatic GEJ/gastric cancer
II NCT01145404 Lapatinib ± capecitabine HER2+ metastatic GEJ cancer
II NCT01486992 mFOLFIRI + nimotuzumab (EGFR antibody) Second-line metastatic ESCC
III NCT01196390 Paclitaxel/carboplatin + radiation ± trastuzumab Locally advanced esophageal/GEJ adenocarcinoma
VEGF
II NCT00354679 Preoperative irinotecan/cisplatin/radiation and bevacizumab Completed accrual–no increase pCR, PFS, OS
MET
I/II NCT01611857 FOLFOX +tivantinib (c-Met inhibitor) First-line molecularly unselected metastatic EAC/
GEJ/gastric cancer
III NCT01662869 mFOLFOX6 ± onartuzumab (MetMAb) Metastatic HER2-negative, MET-positive GEJ cancer
mTOR
I NCT01231399 Everolimus + mFOLFOX6 Metastatic GEJ cancer
I/IIB NCT01490749 Everolimus/XELOX/carboplatin and radiation Locally advanced ESCC or EAC
Immune-Modulating Agents
I NCT01258868 Adjuvant ISCOMATRIX autologous tumor vaccine and celecoxib Resected ESCC or EAC
I NCT01284231 MEDI-565 (CEA/CD3 bispecific antibody T-cell activator) Advanced GI adenocarcinomas including GEJ cancer
II NCT01585987 Ipilimumab postchemotherapy with platinum/fluoropyrimidine Metastatic GEJ/gastric cancer
Other Target/Pathway-Specific Agents
I NCT01460888 Concurrent olaparib (PARP inhibitor)/radiation Locally advanced GEJ cancer or ESCC/EAC
I NCT01183559 Preoperative vandetanib (targets VEGFR, EGFR, and RET) 
carboplatin/5-FU/radiation
Locally advanced resectable ESCC/EAC/GEJ tumors
II NCT01260701 MK2206 (Akt inhibitor) Second-line metastatic GEJ/gastric cancer
I NCT01671774 iMAB362 (antibody-targeting CLDN18.2 cell surface antigen) + 
zoledronic acid
CLDN18.2 expression-positive metastatic esophageal/
GEJ or gastric cancer
II NCT00982592 FOLFOX ± vismodegib (Hedgehog inhibitor) Metastatic GEJ/gastic cancer
II NCT01457846 AZD4547 (FGFR inhibitor) vs. paclitaxel FGFR2 FISH-amplified second-line advanced 
esophageal/GEJ/gastric cancer
Biomarker-Driven
II NCT01372202 CHFR methylation, paclitaxel Recruiting
EGFR, epidermal growth factor receptor; HER-2, human epidermal growth factor receptor 2; pCR, pathological complete response; GEJ, gastro-esophageal junction; ESCC, 
esophageal squamous cell carcinoma; EAC, esophageal adenocarcinoma; VEGF, vascular endothelial growth factor receptor; FGFR, fibroblast growth factor receptor; FISH, fluorescence 
in situ hybridization; PFS, progression-free survival; OS, overall survival; CHFR, checkpoint with Forkhead-associated and RING finger domains. PARP, poly-ADP-ribose polymerase.
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The targeting of HER2 is now being assessed for earlier-
stage disease in the ongoing phase III RTOG 1010 neoadjuvant 
study, combining trastuzumab with paclitaxel, carboplatin, 
and radiation for HER2-positive patients (Table 5).80
Lapatinib, which is a dual small-molecule TKI of both 
EGFR and HER2, has been evaluated in two phase II trials in 
unselected advanced esophageal and GE junction adenocarci-
nomas, and seems to have limited activity with response rates 
varying from 0% to 9%.81,82 The ongoing phase III LOGIC 
trial, evaluating capecitabine/oxaliplatin ± lapatinib as first-
line therapy, and the TYTAN trial, a phase III Asian study of 
lapatinib in combination with paclitaxel as second-line ther-
apy, will help define its role in preselected patients with HER2 
FISH-amplified tumors.
Vascular endothelial growth factor
In esophageal cancer, vascular endothelial growth 
factor (VEGF) is overexpressed in 30% to 60% of patients, 
and several studies have demonstrated a correlation between 
high levels of VEGF expression and advanced stage and poor 
survival postesophagectomy.83–86 Anti-VEGF strategies that 
have been evaluated in esophageal cancer include the use of 
the monoclonal antibody, bevacizumab, and the multitarget 
TKIs, sorafenib and sunitinib. In operable esophageal cancer, 
a phase II study investigated the addition of bevacizumab 
to cisplatin/irinotecan as induction therapy with concurrent 
radiation before esophagectomy.87 Squamous cell histology 
was excluded because of bleeding concerns. Although 
the addition of bevacizumab was well tolerated, it did not 
demonstrate improved efficacy, with pCR rates inferior to 
that of historical controls. The ongoing MAGIC II trial is a 
multicenter, open-label, phase II/III randomized trial in the 
United Kingdom, which is currently evaluating perioperative 
ECX ± bevacizumab. The target accrual of 950 patients is 
expected by 2013.
In the metastatic setting, a multicenter, phase II, first-
line trial evaluated the addition of bevacizumab to cisplatin/
irinotecan in 47 patients.88 The addition of bevacizumab sig-
nificantly improved time to tumor progression (TTP) (8.3 
months; 95% CI, 5.5–9.9 months), compared with historical 
TTP of 5 months, and OS was 12.3 months (95% CI, 11.3–
17.2 months). A second trial combined bevacizumab with 
modified DCF in 44 patients. The overall response rate was 
67%, median PFS was 12 months (95% CI, 8.8–26 months), 
and median OS 16.8 months.89 Toxicities were similar to the 
known side effects of bevacizumab use, although gastric per-
foration was reported in approximately 2% of cases. In the 
second-line setting, the combination of bevacizumab and 
docetaxel has been evaluated in 26 patients and demonstrated 
an impressive overall response rate of 24% in 17 evaluable 
patients, although with a 12% risk of a GI bleed and 8% risk of 
a thromboembolic event.90 The recently published AVAGAST 
study showed that, although the addition of bevacizumab to 
chemotherapy prolonged PFS, there was no evidence of an 
OS advantage.91 Attempts to develop predictive biomarkers 
are ongoing.92
Sorafenib and sunitinib have been evaluated in a num-
ber of phase II clinical trials in metastatic upper GI tumors 
that demonstrated limited activity.93,94 Strategies targeting 
VEGF have ultimately been disappointing to date, and at pres-
ent patients are advised not to receive these agents outside an 
approved clinical trial.
MET
The c-MET oncogene is reported to be amplified in 
approximately 10% to 15% of upper GI tumors; however, 
this incidence may be as low as 2% in Western populations.95 
Expression has been correlated with adenocarcinoma histol-
ogy, more advanced stage, and worse prognosis.96,97 Several 
agents targeting MET are in clinical development for the treat-
ment of gastro-esophageal cancer. Onartuzumab (MetMAb) 
is a humanized monovalent monoclonal antibody-targeting 
MET, which is being investigated in a randomized phase II 
study in combination with mFOLFOX6 for metastatic HER2-
negative GEJ adenocarcinoma.98 Recently crizotinib has shown 
preliminary efficacy in a small population of patients with 
advanced GEJ adenocarcinomas harboring c-MET amplifica-
tion.95 The monoclonal antibody, rilotumumab (AMG-102), 
which targets MET, is currently undergoing phase III investi-
gation combined with ECX chemotherapy in advanced MET 
IHC-positive gastric or GEJ cancer.99 Rilotumumab combined 
with FOLFOX versus FOLFOX/panitumumab is also being 
studied in unselected advanced GEJ tumor patients in a first-
line randomized phase II study in France.100 Tivantinib (ARQ-
197), a selective MET TKI, is being combined with FOLFOX 
in the first-line setting for metastatic GEJ and gastric cancer 
patients not selected for MET expression. Ongoing studies of 
MET-targeted agents are summarized in Table 5.
Future Directions
The ongoing Eastern Cooperative Oncology Group 
2208 trial is investigating the role of IMC-A12 (cixutu-
mumab), a monoclonal antibody targeting insulin-like growth 
factor–1R, as a second-line agent in metastatic esophageal 
cancer given with weekly paclitaxel. iMAB362, a monoclonal 
antibody-targeting cell-surface antigen Claudine 18.2, which 
is expressed in 70% of gastric cancers and 30% of esophageal 
cancers, is in early-phase development. Small-molecule fibro-
blast growth factor receptor (FGFR) kinase inhibitors are also 
in clinical development for fibroblast growth factor receptor 
2–amplified advanced EAC, GEJ cancer, and gastric cancer. 
An additional area of research involves epigenetic therapy, 
and we are currently evaluating checkpoint with Forkhead-
associated and RING finger domains (CHFR) gene methyla-
tion as a predictor of sensitivity to taxane-based chemotherapy 
in both operable and metastatic esophageal cancer (Table 5). 
Epigenetic therapeutic trials using the demethylating agent, 
5-azacytidine, given in combination with a histone deacety-
lase inhibitor are also in development.
The hedgehog pathway is another potential target with 
the oral TKI, vismodegib, which has recently been approved 
for the treatment of basal cell carcinoma and is being inves-
tigated in combination with chemotherapy for advanced GEJ 
tumors (Table 5).
Next-generation sequencing of esophageal cancer is 
an exciting area of investigation with recent evidence report-
ing the pivotal role of NOTCH1-mediated signaling in ESCC 
tumor suppression.101 NOTCH1 is frequently mutated in 
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ESCC, and plays a key role in tumorigenesis, although non-
mutually exclusive mutations of TP53 also occur. Recently, 
the exomic sequencing of ESCC and EAC in the United States 
and China has suggested that NOTCH1 mutations occur in 
ESCC in America, but not in China, and that these muta-
tions may lead to loss of tumor-suppressor function. FBXW7 
mutations may also drive ESCC tumorigenesis independent 
of NOTCH1 through loss of tumor suppression function. In 
EAC, carcinogenic mutations seem to be present from the 
development of Barrett’s esophagus, suggesting that impor-
tant events occur very early in tumorigenesis.
CONCLUSION
In the last few years, randomized controlled trials 
have shown a significant survival advantage for preoperative 
CRT with a predicted 5-year survival of up to 49% for the 
multimodality approach, demonstrated in the CROSS trial. 
Unfortunately, significant breakthroughs in the use of tar-
geted agents has been limited to the addition of trastuzumab 
to chemotherapy for HER2-positive advanced GEJ tumors. 
Ethnic differences are becoming apparent but next-generation 
sequencing has failed to demonstrate significant oncogenic 
targets, indicating that alternative approaches, such as epigen-
etic and immunotherapeutic strategies, should be investigated 
if we are to improve outcomes in this heterogenous and diffi-
cult-to-treat tumor.
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